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BREATHE: A mirror on an under-recognised medical
condition
Chronic obstructive pulmonary disease (COPD) is a frequent
and disabling chronic respiratory disorder which affects
over sixty million people worldwide.1 This is comparable
to the number of people with coronary artery disease and
higher than that for schizophrenia, epilepsy or HIV infection.
However, in comparison with these conditions which
have high visibility in contemporary society, awareness
of COPD is limited, both among the general public and
among healthcare professionals. Nonetheless, due to the
invalidating nature of the disease, its burden is high in
terms of hospitalisation and emergency care, need for long-
term medication and interference with work and social
activities. In order to increase awareness of COPD, it is
important to collect more comprehensive information on
epidemiology, on burden of disease and on quality of care.
This information can be used to guide healthcare policies
designed to improve standards of care and to reduce the
burden of disease to both individual patients and society.
This is particularly relevant for developing countries where
information on COPD is particularly limited and where
priorities for healthcare spending frequently lie elsewhere.
Over the past two decades, GlaxoSmithKline has funded a
number of international initiatives to collect reliable and
systematic data on COPD. The latest ﬁndings are described
in this supplement, as part of the BREATHE study, which was
conducted in ten countries in the Middle East and North
Africa and in Pakistan. The BREATHE study has revealed a
high prevalence of COPD, consistent with the high rate of
cigarette smoking in this region. Furthermore, the existence
of risk factors other than cigarette smoking (waterpipe
smoking and indoor pollution) is a speciﬁc feature for this
region of the world, which may have consequences for who
develops COPD and how their disease affects them. The
study has also revealed a low rate of diagnosis, low levels
of patient awareness and a low proportion of patients who
are receiving adequate treatment. This is associated with
high levels of healthcare resource utilisation and signiﬁcant
disability. Finally, the BREATHE study helped validate the
Arabic and Turkish versions of the CAT questionnaire, a
simple patient-reported tool. It was also the ﬁrst time this
questionnaire was used in the general population, revealing
the potential for it to be used for case identiﬁcation in
primary care. We hope that the ﬁndings of the BREATHE
study, together with other local studies, will be of use to
improve standards of care for patients with COPD in this
region of the world.
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